The latest news, announcements and press releases from Heartbeat.bio.
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases.
The partnership addresses a high unmet need in cardiovascular health. Genetic cardiomyopathies - including hypertrophic, dilated, and arrhythmogenic forms - are a leading cause of heart failure and sudden cardiac death, particularly among younger individuals. Across major pharmaceutical markets (US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan), approximately one million people are affected, many of whom face limited treatment options and a high burden of disease.
This is the News section of the company profile page for Heartbeat.bio on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
